OncoSec Medical Inc (ONCSQ)

[guti]

A future combination study of Keytruda and ImmunoPulse IL-12 might be in the works.
Oncosec in May 2015 began a Sponsored Research Agreement with Massachusetts General Hospital. Under the agreement, researchers planned to evaluate ImmunoPulse IL-12, in a Human Papilloma Virus (HPV) tumour mouse model. Sara I. Pai, MD, PhD is serving as the principal investigator for the pre-clinical study. She is an expert in HPV-associated oropharyngeal cancer and has performed extensive research to better understand how cancer cells evade the immune system and how this process of immune evasion can be reversed.

"Intratumoural delivery of cytokines, such as IL-12, has the potential to alter the tumour microenvironment while minimizing the attendant systemic toxicity associated with other immunotherapeutic target delivery systems," said Dr. Pai.

In January 2016, Dr. Pai will begin enrollment for a phase 2 study that is sponsored by Massachusetts General Hospital with Merck as the collaborator. The tittle is Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients with Laryngeal, Tracheal and/or Pulmonary Involvement. The research will evaluate Pembrolizumab as a treatment for Recurrent Respiratory Papillomatosis. In patients who have RRP, virtually 100% of the time it's caused by HPV DNA. For that reason, mostly children and young adults are diagnosed with the disease.